[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100573994":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":10,"centralContacts":17,"locations":23,"responsibleParty":40,"collaborators":44,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":49,"sex":54,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":10,"studyType":60,"phases":10,"briefSummary":61,"conditions":62,"keywords":65,"overallStatus":70,"whyStopped":10,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Zhejiang University","OTHER",[8],{"label":9,"type":10,"description":9,"interventionNames":11},"Patient Self-Control",null,[12],"Other: 99mTc-FDPH46 SPECT\u002FCT Imaging",[14],{"type":6,"name":15,"description":15,"armGroupLabels":16,"otherNames":10},"99mTc-FDPH46 SPECT\u002FCT Imaging",[9],[18],{"name":19,"role":20,"phone":21,"phoneExt":10,"email":22},"Zhang Jun","CONTACT","+（86）15088608182","1505156@zju.edu.cn",[24],{"facility":25,"status":10,"city":26,"state":27,"zip":28,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"No. 79, Qingchun Road, Shangcheng District, Hangzhou City, Zhejiang Province, China.","Hangzhou","Zhejiang","310000","China","CN",{"type":32,"coordinates":33},"Point",[34,35],120.16142,30.29365,{"lat":35,"lon":34},[38],{"name":19,"role":20,"phone":39,"phoneExt":10,"email":22},"+(86)15088608182",{"type":41,"investigatorFullName":42,"investigatorTitle":43,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Zhang jun","Deputy Chief Physician",[45],{"name":46,"class":6},"First Affiliated Hospital of Zhejiang University","100573994","clinical-application-of-99mtc-fdph46-spectct-imaging-in-malignant-solid-tumor-a-prospective-exploratory-study-100573994",false,"NCT06753513","Clinical Application of 99mTc-FDPH46 SPECT\u002FCT Imaging in Malignant Solid Tumor: a Prospective Exploratory Study","99mTc；FAPI；mCi","Inclusion Criteria:\n\n1. Patients who are clinically suspected or diagnosed with malignant solid tumors.\n2. Ages between 18 to 80 years old.\n3. Stable vital signs, ECOG score of 0-2, capable of tolerating and cooperating with the 99mTc-FDPH46 SPECT\u002FCT examination.\n4. Subjects who are willing to undergo the 99mTc-FDPH46 SPECT\u002FCT examination and have signed the informed consent form.\n\nExclusion Criteria:\n\n1. Those who can not understand, comply with the research protocol or are unable to sign the informed consent form.\n2. Contraindications for SPECT imaging (including pregnant women, nursing women, women of childbearing age with recent plans to conceive, etc.).\n3. Unstable vital signs, ECOG score \\>2, unable to tolerate or cooperate with the 99mTc-FDPH46 SPECT\u002FCT examination process.","ALL","18 Years","80 Years",{"count":58,"type":59},20,"ESTIMATED","OBSERVATIONAL","The goal of this observational study aims to preliminarily evaluate the diagnostic efficacy of 99mTc-FDPH46 SPECT\u002FCT in malignant solid tumors (compared to the pathological gold standard). The main questions it aims to answer are:\n\n* What is the diagnostic efficacy of 99mTc-FDPH46 in malignant solid tumors, compared to the pathological gold standard?\n* What is the biodistribution, tumor uptake and safety of 99mTc-FDPH46 SPECT\u002FCT in patients with malignant solid tumors?\n\nParticipant Will:\n\n• Patients with clinically suspected or diagnosed malignant solid tumors who are willing to undergo 99mTc-FDPH46 SPECT\u002FCT examination and sign an informed consent form.",[63,64],"Malignant Tumors","Solid Tumor Malignancy",[66,67,68,69],"99mTc","FDPH46","SPECT","Malignant Solid Tumor","NOT_YET_RECRUITING","2024-12-22",{"date":73,"type":74},"2024-12-31","ACTUAL",{"date":76,"type":59},"2024-12-28",{"date":78,"type":59},"2026-12-31",{"name":5,"class":6},1]